Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company released an investor presentation, revealing strong top-line growth in 2025. Group revenue jumping 56% year-on-year to US$804 million, and underlying profitability supported by a positive cash balance of US$142 million.

What did Telix Pharmaceuticals report?

• Group revenue of US$804 million, up 56% from FY25, meeting upgraded guidance
• Precision Medicine revenue rose 22% year on year to US$622 million
• RLS Radiopharmacies contributed US$170 million in revenue after acquisition
• Group EBITDA of US$40 million
• Positive cash balance of US$142 million as at year end
• Investment of over US$500 million across R&D and strategic initiatives

What else do investors need to know?

Telix’s commercial momentum continues, with Q1 2026 unaudited group revenue climbing 11% quarter on quarter to US$230 million. The company is progressing multiple clinical-stage assets, with four therapies now in pivotal or phase 3 trials targeting prostate, kidney, and brain cancers.

Regulatory advances have been made for new products, including Pixclara (TLX101-Px), which has a US FDA target decision date of 11 September 2026, and Illuccix accepted for review in China. Telix has also signed a new global collaboration with Regeneron to co-develop radiopharmaceutical therapies for solid tumours, bringing in US$40 million upfront with potential for further milestone payments.

What’s next for Telix Pharmaceuticals?

Looking ahead, Telix has issued FY26 revenue guidance in the range of US$950 million to US$970 million, with continued growth expected in its Precision Medicine segment and full-year contributions from recent acquisitions. R&D investment is targeted between US$200 million and US$240 million, mainly focused on advancing late-stage therapeutics and delivery of clinical milestones.

The company aims to launch new precision imaging and therapy products, complete key clinical trials, and enhance its manufacturing capacity with projects underway in Europe and Japan. Management emphasises reinvesting earnings to support long-term sustainable growth and innovation in radiopharma.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 41%, underperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• Qantas Airways flags higher fuel costs and capacity changes in FY26 update
• Cleanaway Waste Management trims FY26 outlook on fuel challenges
• Westpac Banking Corporation: Items impacting first-half 2026 results
• 3 quality ASX shares I’d buy while everyone else is nervous

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.